Novo Nordisk
NVO
484 hedge funds and large institutions have $6.59B invested in Novo Nordisk in 2017 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 149 increasing their positions, 176 reducing their positions, and 38 closing their positions.
68% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 38
51% more call options, than puts
Call options by funds: $45.5M | Put options by funds: $30.1M
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
19% more capital invested
Capital invested by funds: $5.53B → $6.59B (+$1.06B)
5% more funds holding
Funds holding: 463 → 484 (+21)
0.35% less ownership
Funds ownership: 16.02% → 15.67% (-0.35%)
15% less repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 176
Top Buyers
Top Sellers
NVO Hedge Fund Activity: Q2 2017 in Review
484 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2017, worth a combined $6.59B — up 19% from $5.53B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new NVO positions and 38 closed out — a net gain of 26 holders — while 149 added to existing stakes and 176 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $53.8M. The largest seller was Renaissance Technologies, cutting an estimated $116M.
- 484 institutional investors held Novo Nordisk (NVO) as of Q2 2017, up from 463 in Q1 2017.
- Funds reported $6.59B of Novo Nordisk stock for Q2 2017, up 19% quarter-over-quarter.
- 64 funds opened new Novo Nordisk positions in Q2 2017 and 38 closed out, a net change of +26 holders.
- The largest Novo Nordisk buyer in Q2 2017 was Fisher Asset Management, an estimated $53.8M added.
- The largest Novo Nordisk seller in Q2 2017 was Renaissance Technologies, an estimated $116M sold.
Based on aggregated 13F filings for Q2 2017.